Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Adamson

Showing results (31-40 of 176) with videos related to

Pageof 18
Sort By:
Pediatric Blood & Cancer|August 19, 2011
Preclinical evaluation of pemetrexed in pediatric solid tumorsRobin E Norris, Eric F Rappaport, Peter C Adamson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Pediatric phase I trials in oncology: an analysis of study conduct efficiencyDebra P Lee, Jeffrey M Skolnik, Peter C Adamson
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|March 27, 2003
Propofol pharmacokineticsAthena F Zuppa, Mark A Helfaer, Peter C Adamson
JCO Oncology Practice|April 9, 2020
Survivorship Care Plans and the Commission on Cancer Standards: The Increasing Need for Better Strategies to Improve the Outcome for Survivors of CancerAnne H Blaes, Peter C Adamson, Lewis Foxhall, et al.
JAMA Oncology|June 4, 2018
New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A ReviewSonya Das, Raphaël Rousseau, Peter C Adamson, et al.
Nature Reviews. Clinical Oncology|September 17, 2014
Drug discovery in paediatric oncology: roadblocks to progressPeter C Adamson, Peter J Houghton, Giorgio Perilongo, et al.
Anesthesiology|October 21, 2016
CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!Scott D Cook-Sather, Peter C Adamson, Jin Li, et al.
Pediatric Blood & Cancer|September 17, 2013
Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumorsRobin E Norris, Peter C Adamson, Vu T Nguyen, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 6, 2010
A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasmaEmily Lipsitz, Ganesh Moorthy, Yael Mosse, et al.
Cancer Chemotherapy and Pharmacology|September 28, 2005
A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancerJeffrey M Skolnik, Jeffrey S Barrett, Heng Shi, et al.
Pageof 18

Showing results (31-40 of 176) with videos related to

Sort By:
Pageof 18
Pediatric Blood & Cancer|August 19, 2011
Preclinical evaluation of pemetrexed in pediatric solid tumorsRobin E Norris, Eric F Rappaport, Peter C Adamson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Pediatric phase I trials in oncology: an analysis of study conduct efficiencyDebra P Lee, Jeffrey M Skolnik, Peter C Adamson
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|March 27, 2003
Propofol pharmacokineticsAthena F Zuppa, Mark A Helfaer, Peter C Adamson
JCO Oncology Practice|April 9, 2020
Survivorship Care Plans and the Commission on Cancer Standards: The Increasing Need for Better Strategies to Improve the Outcome for Survivors of CancerAnne H Blaes, Peter C Adamson, Lewis Foxhall, et al.
JAMA Oncology|June 4, 2018
New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A ReviewSonya Das, Raphaël Rousseau, Peter C Adamson, et al.
Nature Reviews. Clinical Oncology|September 17, 2014
Drug discovery in paediatric oncology: roadblocks to progressPeter C Adamson, Peter J Houghton, Giorgio Perilongo, et al.
Anesthesiology|October 21, 2016
CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!Scott D Cook-Sather, Peter C Adamson, Jin Li, et al.
Pediatric Blood & Cancer|September 17, 2013
Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumorsRobin E Norris, Peter C Adamson, Vu T Nguyen, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 6, 2010
A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasmaEmily Lipsitz, Ganesh Moorthy, Yael Mosse, et al.
Cancer Chemotherapy and Pharmacology|September 28, 2005
A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancerJeffrey M Skolnik, Jeffrey S Barrett, Heng Shi, et al.
Pageof 18